World Journal of Surgical Oncology最新文献

{"title":"GPR17 Suppresses Triple-Negative Breast Cancer Progression and Serves as an Independent Prognostic Biomarke.","authors":"Guannan Liu, Meng Wei, Yichuan Zhang, Zhong Lu, Min Zhang","doi":"10.1186/s12957-026-04418-z","DOIUrl":"10.1186/s12957-026-04418-z","url":null,"abstract":"<p><strong>Background: </strong>G protein-coupled receptor 17 (GPR17), a Gi protein-coupled receptor, has been defined poorly about its roles and clinical significance in triple-negative breast cancer (TNBC).</p><p><strong>Purpose: </strong>The biological expression profile, prognostic value and functional roles of GPR17 in TNBC were elucidated in the present study.</p><p><strong>Methods: </strong>Differentially expressed genes were screened through comprehensive bioinformatics analyses of the GSE233242 dataset. GPR17 expression patterns and their prognostic significance in TNBC were evaluated based on the UALCAN, bc-GenExMiner v4.8 and KM-Plotter databases. Prognostic correlations of GPR17 were further validated in a retrospective cohort comprising 163 TNBC patients. In vitro functional assays for cell proliferation, migration and invasion were conducted in MDA-MB-231 and MDA-MB-453 cells after GPR17 overexpression.</p><p><strong>Results: </strong>GPR17 was significantly downregulated in TNBC tumor tissues (p < 0.001), and reduced GPR17 expression was associated with more aggressive tumor phenotypes in TNBC patients. GPR17 expression was closely correlated with clinical T stage and lymph node metastasis, and was identified as an independent prognostic factor for the disease. Ectopic GPR17 overexpression significantly suppressed the proliferative, migratory and invasive capacities of MDA-MB-231 and MDA-MB-453 TNBC cell lines.</p><p><strong>Conclusion: </strong>GPR17 holds potential as a novel prognostic biomarker for TNBC, with its expression levels closely associated with tumor progression and able to predict clinical outcomes in TNBC patients.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13422291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor count and risk of lymph node metastasis in multiple rectal neuroendocrine tumors: an individual-level pooled analysis.","authors":"Jianguo Xu, Jian Shi, Yu Mu, Nan Zhou, Yechao Du, Weiwei Lai, Zhaoyong Wang, Lina Zhang, Zhongyan Chen, Qian Ma, Yong-Ping Yang","doi":"10.1186/s12957-026-04441-0","DOIUrl":"10.1186/s12957-026-04441-0","url":null,"abstract":"<p><strong>Background: </strong>Multiple rectal neuroendocrine tumors (RM-NETs) are a rare and underrecognized subtype of rectal neuroendocrine neoplasms. Although these tumors are usually small and well differentiated, their risk of lymph node metastasis (LNM) may be underestimated when tumor size is considered alone. Current guidelines do not distinguish RM-NETs from solitary lesions. This study investigated the association between tumor count and LNM in patients with RM-NETs.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Embase, Web of Science, and Scopus was performed from database inception to September 30, 2025. Published case reports and case series describing two or more histologically confirmed rectal NETs were screened for eligibility, and one additional institutional case was included. Individual-level clinicopathological data were extracted and pooled. Receiver operating characteristic analysis was used to explore the discriminative ability of tumor count for LNM, and exploratory multivariable logistic regression was performed to identify factors associated with LNM.</p><p><strong>Results: </strong>A total of 46 patients were included, comprising 45 patients from 17 published studies and one institutional case. The median age was 57 years, and 80.4% of patients were male. Most tumors measured ≤ 10 mm (91.3%). LNM was identified in 8 patients (17.4%). ROC analysis suggested an exploratory threshold of approximately seven lesions. Patients with ≥ 7 tumors had a significantly higher incidence of LNM than those with fewer than 7 tumors, with rates of 46.7% and 3.2%, respectively. In exploratory multivariable analysis, tumor count ≥ 7 remained associated with LNM.</p><p><strong>Conclusions: </strong>Tumor count may help identify patients with RM-NETs who are at increased risk of LNM. In this pooled analysis, the exploratory threshold of approximately seven lesions should be regarded as hypothesis-generating rather than as a definitive clinical cutoff. In patients with extensive multifocal disease, this finding may warrant closer nodal staging and multidisciplinary discussion, even when the maximum lesion size is small. Further validation in larger multicenter cohorts is warranted.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148278992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a multimodal bundled intervention on quality of recovery after laparoscopic colorectal cancer surgery: a single-center, single-blind, pragmatic randomized controlled trial.","authors":"Jiayi Ren, Qiuyu Yang, Haoxiang He, Jin Li, Hang Gao, Chen Yang, Yan Cao, Yuting Wen, Chen Chen, Marim Kandil, Jiming Tao","doi":"10.1186/s12957-026-04454-9","DOIUrl":"10.1186/s12957-026-04454-9","url":null,"abstract":"<p><strong>Background: </strong>Despite the minimally invasive nature of laparoscopic colorectal surgery, postoperative recovery is frequently compromised by pain, fatigue, and delayed gastrointestinal function. Current rehabilitation strategies largely rely on unimodal approaches, and evidence for structured multimodal bundled interventions is limited. This study aimed to evaluate whether a multimodal bundled intervention comprising electroacupuncture, abdominal massage, structured breathing training, and symptom-titrated supervised ambulation improves quality of recovery in patients undergoing laparoscopic surgery for stage I-III colorectal cancer.</p><p><strong>Methods: </strong>This single-center, single-blind, parallel-group, pragmatic randomized controlled trial randomized 105 patients to either a multimodal bundled intervention plus standard care or standard care alone. The intervention group received electroacupuncture and structured breathing training from postoperative day 1 to 7, with abdominal massage and symptom-titrated supervised ambulation added from postoperative day 4 to 7. The primary outcome was the trajectory of the Quality of Recovery-15 (QoR-15) score assessed at postoperative days 3, 7, and 30. Statistical analyses followed a modified intention-to-treat principle.</p><p><strong>Results: </strong>Of 105 randomized patients, 90 (45 per group) were included in the final analysis. A significant group-by-time interaction was observed for QoR-15 scores (P = 0.043). While no significant between-group differences were found at postoperative days 3 or 7, the intervention group demonstrated significantly higher QoR-15 scores at postoperative day 30 (mean difference 11.33; 95% confidence interval 3.41 to 19.26; P = 0.005). Secondary outcomes, including pain intensity and perceived exertion, showed favorable between-group differences at later postoperative assessments. No serious intervention-related adverse events were reported.</p><p><strong>Conclusions: </strong>In this single-center pragmatic randomized controlled trial, the multimodal bundled intervention did not significantly improve QoR-15 scores during the early postoperative period at POD3 or POD7. However, it was associated with a clinically meaningful improvement in QoR-15 at POD30. These findings suggest a potential medium-term patient-reported recovery benefit after laparoscopic colorectal cancer surgery, but they should not be interpreted as evidence of accelerated early ERAS-related recovery.</p><p><strong>Trial registration: </strong>ChiCTR2400085191. Registered on June 3, 2024.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPP1 promotes lymph node metastasis and malignant progression of head and neck squamous cell carcinoma by activating FAK-AKT signaling pathway.","authors":"Jingyan Li, Min Pan, Mengna Wang, Tianhao Wu, Youlan Zhang, Zhihai Wang, Quan Zeng","doi":"10.1186/s12957-026-04377-5","DOIUrl":"10.1186/s12957-026-04377-5","url":null,"abstract":"<p><strong>Background: </strong>Lymph node metastasis is a critical determinant of poor prognosis in head and neck squamous cell carcinoma (HNSCC). Secreted phosphoprotein 1 (SPP1) has been implicated in the progression of multiple malignancies; however, its clinical relevance and potential molecular mechanisms in HNSCC remain not fully understood. This study aims to comprehensively characterize the expression profile, biological functions, and potential molecular mechanisms of SPP1 during HNSCC progression.</p><p><strong>Methods: </strong>Public datasets were analyzed to assess SPP1 expression and its association with clinicopathological features and patient outcomes. Forty surgical specimens of head and neck squamous cell carcinoma (including adjacent normal tissues, non-metastatic tumors and lymph node metastatic tumors) were collected and verified by immunohistochemistry, quantitative PCR and Western blotting. Then, cellular functional assays including CCK-8, EdU synthesis, wound healing, and Transwell assays were performed to evaluate the effects of SPP1 knockdown and overexpression on the proliferation and invasion of head and neck squamous cell carcinoma cells. Transcriptome sequencing was performed in SPP1 knockdown cells and control cells (n = 3 in each group), followed by differential expression analysis, enrichment analysis, and gene set enrichment analysis to explore potential mechanisms.</p><p><strong>Results: </strong>The results showed that SPP1 expression was significantly increased in HNSCC tissues compared with adjacent normal tissues and was associated with lymph node metastasis, advanced tumor stage, and poor prognosis. Experimental validation in clinical samples confirmed that SPP1 expression was increased in tumors, especially in cases with lymph node metastasis. The results of the cell function experiments showed that the knockout of the SPP1 gene significantly inhibited the proliferation and migration abilities of HNSCC, while when the SPP1 gene was overexpressed, these functions of the cells were enhanced. Transcriptomic profiling identified 1,853 differentially expressed genes following SPP1 knockdown, with enrichment in pathways related to extracellular matrix organization, focal adhesion, and oncogenic signaling. Gene set enrichment analysis further supported the involvement of extracellular matrix remodeling and migration-related biological processes.</p><p><strong>Conclusions: </strong>SPP1 promotes the malignant progression of HNSCC and is closely associated with lymph node metastasis. Its tumor-promoting effects may be mediated, at least in part, through regulation of extracellular matrix- and adhesion-related signaling pathways. These findings highlight SPP1 as a potential biomarker and therapeutic target in HNSCC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13508293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic resection or radical gastrectomy? Risk factors for lymph node metastasis in early gastric cancer: a systematic review and meta-analysis.","authors":"Yike Zhang, Haozhe Wang, Tianhang Luo","doi":"10.1186/s12957-026-04455-8","DOIUrl":"10.1186/s12957-026-04455-8","url":null,"abstract":"<p><strong>Background: </strong>The management of EGC hinges on accurate LNM risk assessment, guiding the critical choice between endoscopic resection (ER) and radical gastrectomy. This study provides a comprehensive evidence synthesis to optimize treatment selection.</p><p><strong>Methods: </strong>This systematic review and meta-analysis (PROSPERO CRD420251152013) was conducted in accordance with PRISMA guidelines. A comprehensive literature search of PubMed, Web of Science, Scopus, and Embase was performed for studies published up to September 5, 2025. Study quality and risk of bias were assessed using the ROBINS-I tool, and the certainty of evidence for each association was evaluated with the GRADE framework. Statistical heterogeneity was investigated, and the sources were explored through meta-regression where appropriate.</p><p><strong>Results: </strong>One hundred one studies were included. Meta-analysis identified predictors: LVI (OR = 9.04, with LVI negative as reference, 95% CI: 7.18-11.37), mucosal invasion (T1a) (OR = 0.20, with T1b as reference, 95% CI: 0.19-0.22), tumor size ≤ 2 cm (OR = 0.39, with > 2 cm as reference, 95% CI: 0.36-0.43), differentiated histology (OR = 0.45, with undifferentiated type as reference, 95% CI: 0.40-0.50), PNI (OR = 3.41, with PNI negative as reference, 95% CI: 2.46-4.71), ulceration (OR = 1.68, with ulceration negative as reference, 95% CI: 1.37-2.05), age ≤ 60 years (OR = 1.13, with > 60 years old as reference, 95% CI: 1.06-1.21), male (OR = 0.69, with females as reference, 95% CI: 0.65-0.72), middle location (OR = 0.96, with other parts as reference, 95% CI: 0.90-1.02), CEA > 0.5 ng/mL (OR = 1.35, with CEA ≤ 0.5ng/mL as reference, 95% CI: 1.04-1.75), CA199 > 37 U/mL (OR = 4.02, with CA199 ≤ 37 U/mL as reference, 95% CI: 1.46-11.11), CA125 (OR = 1.17, with CA125 ≤ 35 U/mL as reference, 95% CI: 0.48-2.81), CA724 (OR = 1.33, with CA724 ≤ 7 U/mL as reference, 95% CI: 0.84-2.11). All reported pooled ORs represent unadjusted estimates derived from univariate data.</p><p><strong>Conclusion: </strong>This meta-analysis provides a comprehensive evidence base for risk stratification in EGC. By distinguishing patients suitable for ER from those requiring radical operation, our findings serve as a critical guide for optimizing clinical practice and resolving the therapeutic dilemma between endoscopy and radical surgery.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serological signatures and pathological features for the management of CEA-negative colorectal cancer: development of combined diagnostic and prognostic nomograms.","authors":"Zhongmao Fu, Zai Luo, Chao Han, Renchao Zhang, Yitian Xu, Yuan Zhang, Jing Qin, Chen Huang","doi":"10.1186/s12957-026-04452-x","DOIUrl":"10.1186/s12957-026-04452-x","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) remains a leading cause of malignancy-related mortality, with prognosis heavily contingent upon early detection. Notably, a significant proportion of CRC patients present with normal preoperative Carcinoembryonic Antigen (CEA) levels, creating a diagnostic blind spot where malignant lesions may be indistinguishable from benign colorectal disease (BCD). This study aimed to develop and validate multidimensional nomograms to accurately diagnose and prognostically stratify patients with CEA-negative CRC.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 553 CEA-negative CRC patients and 200 BCD patients. Optimal biomarker thresholds were determined via ROC analysis. Diagnostic and prognostic predictors were identified using multivariable logistic and Cox regressions. Model performance was evaluated using C-indices, calibration plots, Decision Curve Analysis (DCA), and Clinical Impact Curves (CIC).</p><p><strong>Results: </strong>Of 895 screened CRC patients, 61.8% were CEA-negative. An eight-variable diagnostic model (age, sex, CA50, CA125, CA19-9, WBC, PLR, FAR) demonstrated strong discriminative power, yielding C-indices of 0.886 (training) and 0.895 (validation). For overall survival, a prognostic signature incorporating age, tumor location, Lymph Node Ratio (LNR), Monocyte-to-Lymphocyte ratio (MLR), and Tumor-Stroma Ratio (TSP) achieved C-indices of 0.749 (training) and 0.829 (validation), showing favorable prognostic stratification compared to the AJCC 8th TNM staging system. DCA and CIC confirmed superior clinical net benefit for both models.</p><p><strong>Conclusion: </strong>Integrating systemic inflammatory indices and stromal features provides a potentially useful adjunctive tool for cancer detection and risk assessment. These user-friendly nomograms may assist in personalized prognostication, potentially refining clinical decision-making and patient stratification for therapeutic trials. However, independent external validation is required before clinical implementation due to the single-center design and internally derived cut-offs.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13508322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An integrated analysis of MEN1 reveals its associations with clinical outcomes, cellular pathways, and the immune microenvironment.","authors":"Hao Li, Xinyu Gong, Yanwei Yao, Ping Bi, Qiang Li, Xiaoru Wang, Jian Peng","doi":"10.1186/s12957-026-04460-x","DOIUrl":"10.1186/s12957-026-04460-x","url":null,"abstract":"<p><p>The menin protein, encoded by the Multiple Endocrine Neoplasia Type 1 (MEN1) gene, serves as a critical regulator of cellular processes in human cancers. While menin-targeted therapies are undergoing clinical investigation, a comprehensive pan-cancer analysis of MEN1's diagnostic, prognostic, and immunomodulatory roles remain lacking. Here, we systematically evaluated MEN1 expression patterns and clinical relevance using multi-omics databases and immunohistochemical profiles from the Human Protein Atlas (HPA). MEN1 exhibited ubiquitous expression in normal tissues but was frequently upregulated across multiple malignancies, correlating with adverse survival outcomes. Elevated MEN1 expression demonstrated strong diagnostic utility and positive associations with tumor mutation burden (TMB), suggesting complementary value in cancer detection. Immune landscape analysis revealed significant correlations between MEN1 expression and immune checkpoint genes, as well as immune cell infiltration patterns. Functional characterization implicated MEN1 in activating cell cycle progression, DNA damage response, and oncogenic signaling pathways, as validated through Gene Set Enrichment Analysis (GSEA) and single-sample Gene Set Enrichment Analysis (ssGSEA). These findings position MEN1 as a promising prognostic biomarker and therapeutic target with implications for immuno-oncology and precision medicine.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limb cold therapy for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.","authors":"Danna Wu, Haiwei Bai, Yafei Zhang, Weina Wang","doi":"10.1186/s12957-026-04448-7","DOIUrl":"10.1186/s12957-026-04448-7","url":null,"abstract":"<p><strong>Background: </strong>Paclitaxel, a widely used chemotherapeutic drug for breast cancer, often causes peripheral neuropathy, which impacts patient quality of life and limits treatment dosages. Cold therapy, involving controlled cold application to extremities, has emerged as a potential non-pharmacological intervention to reduce such neurotoxic effects. This study evaluates the effectiveness of limb cold therapy in preventing and reducing severity paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients.</p><p><strong>Methods: </strong>A prospective, randomized controlled study was conducted at the Fourth Hospital of Hebei Medical University from October 2022 to August 2024, involving 200 breast cancer patients undergoing paclitaxel and platinum chemotherapy. Participants were randomized into two groups: the control group receiving standard treatment (n = 103), and the cold therapy group receiving limb cold therapy with ice gloves and socks (n = 97). Outcomes were evaluated across multiple chemotherapy cycles using the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT), National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) scales. Neurophysiological assessments and Activities of Daily Living (ADL) tests were conducted to further evaluate the effects. The primary outcome was the incidence and severity of CIPN, assessed using NCI-CTCAE and CIPNAT. Secondary outcomes included FACT/GOG-Ntx, ADL, and neurophysiological parameters.</p><p><strong>Results: </strong>The cold therapy group showed a significant reduction in chemotherapy-induced peripheral neuropathy (CIPN) severity from the fourth chemotherapy cycle onwards (e.g., fourth cycle CIPN grade 0: 64.95% vs. 44.66% in control, P = 0.013). CIPNAT scores indicated less severe neuropathy symptoms at the fourth cycle (cold therapy: 124.63 ± 59.21 vs. control: 147.79 ± 77.94, P = 0.019) and sixth cycle (cold therapy: 151.93 ± 61.87 vs. control: 169.64 ± 63.82, P = 0.048). FACT/GOG-Ntx scores showed reduced neurotoxicity in the cold therapy group at the fourth cycle (15.48 ± 3.61 vs. 17.12 ± 3.57, P = 0.001) and at multiple follow-ups. ADL scores improved significantly three months post-chemotherapy (cold therapy: 76.96 ± 5.11 vs. control: 74.61 ± 5.21, P = 0.002). Neurophysiological assessments revealed better nerve conduction parameters in the cold therapy group, including decreased distal motor latency (DML) and improved compound muscle action potential amplitude.</p><p><strong>Conclusion: </strong>Limb cold therapy may help mitigate PIPN symptoms, improve quality of life scores, and preserve peripheral nerve function in breast cancer patients.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13495298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148259851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal SMARCA4-deficient undifferentiated carcinoma: a case series and systematic review of the literature.","authors":"Wenjing Ma, Shenda Zhou, Yongta Huang, Xiaofeng Tang, Shimei Wang","doi":"10.1186/s12957-026-04450-z","DOIUrl":"10.1186/s12957-026-04450-z","url":null,"abstract":"<p><strong>Background: </strong>Intestinal SMARCA4-deficient undifferentiated carcinoma (SMARCA4-DUC) is a rare and highly aggressive malignancy. Its clinicopathological features remain poorly defined. No standardized treatment has been established.</p><p><strong>Methods: </strong>We report two new cases and review 18 previously published cases, providing a descriptive summary of clinicopathological, molecular, and therapeutic features.</p><p><strong>Results: </strong>The aggregated 20 cases included 80% males, with a mean age of 56 years. The tumors exhibited diffuse sheet-like growth of epithelioid cells, with rhabdoid morphology observed in 81.25% (13/16) of cases. Necrosis and mitotic activity were frequent. Immunohistochemistry confirmed SMARCA4 loss and variable CK/CK7 expression, while CDX-2 and CK20 were consistently negative. Ki-67 was uniformly high. Although molecular profiling data in this study were limited, TP53 mutations were identified in all three cases with available NGS data. Distant metastasis was present in 41.2% of patients at initial diagnosis. The median overall survival was 11 months (range 1.5-29 months). Chemotherapy responses were poor, but responses to immune checkpoint inhibitors were heterogeneous: two patients achieved sustained complete remission (> 18 months) on pembrolizumab, while three others experienced no benefit.</p><p><strong>Conclusions: </strong>Intestinal SMARCA4-deficient carcinoma is a rare high-grade malignancy with a poor prognosis and currently no standard treatment regimen. In this small aggregated series, two patients achieved durable complete responses to pembrolizumab monotherapy, suggesting that a subset of these tumors may benefit from immune checkpoint inhibitors. However, given the inconsistent responses observed, these preliminary findings require validation in future multicenter, large-scale prospective studies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13491671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of miR-27a-3p/FBXW7 axis by increasing the level of lncRNA AC138128.1 to mitigate gastric cancer progression.","authors":"Shuojun Lu, Shuo Ding, Guihua Fu, Yichuan Zhang, Xingwu Huang","doi":"10.1186/s12957-026-04324-4","DOIUrl":"10.1186/s12957-026-04324-4","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) has a poor prognosis due to its recurrence and metastasis. This research aims to investigate the potential regulatory mechanisms of AC138128.1 in GC.</p><p><strong>Methods: </strong>A total of 124 GC patients were enrolled. RT-qPCR was used to assess AC138128.1, miR-27a-3p, and mRNA levels. Cell proliferation, migration, and invasion were assessed using CCK-8 and Transwell assays, respectively. Kaplan-Meier curves were used to validate patient survival. Targeted interactions among AC138128.1, miR-27a-3p, and FBXW7 were verified via DLR assays, with Pearson correlation analysis assessing relationships among the three groups. GO and KEGG were used to analyze the biological information of miR-27a-3p target genes.</p><p><strong>Results: </strong>AC138128.1 is downregulated in GC tissues, miR-27a-3p level is upregulated. AC138128.1 negatively regulates miR-27a-3p. Patients with GC in the low AC138128.1 level group exhibited lower 5-year survival rates. Transfection with oe-AC138128.1 reduces miR-27a-3p levels, significantly inhibiting cell growth and invasiveness. However, when the miR-27a-3p level is increased, this inhibitory effect is reversed. Additionally, the downstream target genes of miR-27a-3p are primarily enriched in the PI3K-Akt signaling pathway. FBXW7 expression was downregulated in GC tissues. AC138128.1 expression positively correlated with FBXW7, whereas miR-27a-3p expression negatively correlated with FBXW7.</p><p><strong>Conclusions: </strong>This study provides the first evidence that AC138128.1 is downregulated in GC cell lines and holds significant potential as a prognostic biomarker for GC. Low levels of AC138128.1 enhance miR-27a-3p expression, thereby influencing the invasiveness of GC cells and potentially promoting GC progression.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148228569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}